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Griseolic acid inhibited CAMP phosphodiesterase (PDE) at low concentrations, the 1,, being of the order 
of 0.01-0.1 PM. Administration of griseolic acid to rats increased the CAMP level in liver and plasma sever- 
al-fold. It increased glycogen degradation in mouse liver and stimulated lipolysis in isolated rat fat cells. 
Griseolic acid did not block the adenosine-elicited accumulation of CAMP in guinea pig brain slices. It had 
no effect on CAMP-dependent protein kinase from rat liver nor on the adenyl cyclase from rat brain. 
Griseolic acid Phosphodiesterase inhibitor CAMP cGMP Glucagon Theophylline 
1. INTRODUCTION 
Cyclic nucleotide phosphodiesterase (PDE) 
catalyzes the hydrolysis of CAMP or cGMP to 
5 ‘-AMP or 5 ’ -GMP. Since PDE is the only en- 
zyme known to degrade CAMP or cGMP, its 
cellular activity is critical in governing the extent 
and duration of the action of these nucleotides. 
During an extensive search for PDE inhibitors in 
microbial culture broth, we discovered griseolic 
acid from the culture filtrate of Streptomyces 
griseoaurantiacus which had been isolated from a 
soil sample collected in Kyoto-fu, Japan [l]. 
Griseolic acid has a unique structure, resembling 
CAMP with an adenine group in the molecule [2] 
(fig.1). It inhibited PDE in homogenates of 
various tissues at low concentrations and the in- 
hibition was competitive with regard to CAMP, the 
substrate [ 11. 
This paper describes the effect of griseolic acid 
on cyclic nucleotide levels in cells and tissues 
together with its physiological effects. 
Abbreviation: ZSO, concentration required for 50% 
inhibition 
Fig.1. Structure of griseolic acid (C14H130sNs; M, 379) 
and CAMP. 
2. EXPERIMENTAL 
2.1. ‘Assays for PDE activity 
The preparation and assay of cyclic nucleotide 
phosphodiesterases from rat brain were as de- 
scribed [ 11. 
Canine cardiac PDE was separated into 3 major 
forms by DEAE-cellulose chromatography using 
the stepwise lution procedure described by Thomp- 
son et al. [3,4]. Assay of separated PDEs was car- 
ried out essentially according for the method de- 
scribed by Pichard and Cheung [5] with 0.25 ,uM 
CAMP or cGMP as substrate. 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/85/$3.30 0 1985 Federation of European Biochemical Societies 179 
Volume 192, number 2 FEBS LETTERS November 1985 
2.2. Determination of CAMP and cGMP in the 
liver and plasma of rats 
Male Wistar rats (200-220 g body wt) were 
fasted for 18 h, and griseolic acid dissolved in 
saline was injected subcutaneously at a dose of 10 
mg/kg. After 50 min the rats were anesthetized 
with pentobarbital and blood taken from the 
carotid artery. Simultaneously, a leaf of the liver 
was excised, quickly perfused with cold saline and 
frozen with clamps cooled in liquid nitrogen. The 
CAMP and cGMP levels were determined using 
radioimmunoassay kits (Yamasa Shoyu, Chiba, 
Japan) according to Honma et al. [6]. 
2.3. Lipolysis of fat cells 
Isolation of fat cells from epididymal adipose 
tissue of rats was performed according to Rodbell 
[7]. Fat cells (3 x lo5 cells) were incubated with 100 
pg griseolic acid or theophylline in 1.0 ml Krebs 
Ringer bicarbonate (pH 7.4) supplemented with 
4% bovine serum albumin at 37°C with a gas 
phase of 95(r/o 02: 5% CO2 for 2 h with gentle 
shaking. Reaction was terminated by addition of 
an equal volume of cold 7.5% trichloroacetic acid 
and after centrifugation at 3000 rpm for 10 min, 
the supernate was subjected to determination of 
glycerol [8] and CAMP [6]. 
2.4. Determination of blood glucose and liver 
glycogen in mice 
Male ddy mice (20-22 g body wt) were deprived 
of diet at 9 a.m. and the experiments tarted usual- 
ly at 10 a.m. Griseolic acid, glucagon or the vehicle 
(saline) was injected into the tail vein. At time in- 
tervals, mice were decapitated, blood glucose 
determined with a Glucometer (Miles), and a por-, 
tion of the liver excised into ice-cold saline. The 
liver glycogen level was determined by the method 
of Van der Vies [9] with mouse liver glycogen [IO] 
as a standard. 
2.5. Adenosine-elicited accumulation of CAMP 
in guinea pig brain slices 
Cerebral cortex slices (0.26 x 0.26 mm) were 
prepared from male guinea pigs (about 300 g body 
wt), and incubated at 37°C in a nylon cloth dipped 
in Krebs-bicarbonate glucose medium gassed with 
95’?‘0 2: 5% CO2 to lower the basal CAMP level 
[ll, 121. The medium was changed twice. After 
about 60 min, the slices were suspended in fresh 
180 
medium gassed as above, and an aliquot trans- 
ferred to 2 ml (final) Krebs-bicarbonate glucose 
medium containing the agents tested. Incubation 
was performed at 37°C for 5 min with the same gas 
phase and the reaction terminated by addition of 
0.1 ml of 100% trichloroacetic acid. After 
homogenization and centrifugation, the CAMP 
content of the supernate was determined by 
radioimmunoassay [6], and protein of the pellet 
determined according to Bradford [ 131. 
2.6. Other determinations 
CAMP-dependent protein kinase was purified 
from rat liver by the method of Kumon et al. [14], 
and the effect of griseolic acid on the enzyme 
measured in the presence and absence of 1 FM 
CAMP. Rat brain adenyl cyclase was prepared and 
assayed essentially according to Piascik et al. [15]. 
In the assay of calf intestinal adenosine deaminase 
(Sigma), formation of inosine was determined by 
HPLC [16,17]. 
3. RESULTS AND DISCUSSION 
3.1. Inhibitory activity on PDE 
Griseolic acid is a more potent inhibitor of cyclic 
nucleotide PDE than theophylline and papaverine. 
The 150 values (in PM) of griseolic acid, 
theophylline and papaverine with 0.14 FM CAMP 
(0.14 FM cGMP in parentheses) as substrate were 
0.16 (0.63), 360 (196) and 3.6 (13.6), respectively, 
with the supernate of rat brain homogenate as the 
enzyme. The inhibitory effect of griseolic acid 
toward canine cardiac PDEs separated into 3 ma- 
jor forms (PDE I, II, III) was also investigated. 
The Iso values (in nM) for PDE I, II and III with 
0.25 PM CAMP (0.25 FM cGMP) as substrate were 
74 (35), 50 (22) and 18 (65), respectively. 
3.2. Elevation of cyclic nucleotide levels in rats 
CAMP and cGMP levels were determined in the 
liver and plasma 50 min after subcutaneous ad- 
ministration of griseolic acid (10 mg/kg) to rats. In 
the liver, the CAMP level was increased 5-fold and 
that of cGMP 3-fold (fig.2). In plasma, the CAMP 
level was increased 9-fold but the cGMP level only 
1.3-fold. When the experiments were performed by 
oral administration of griseolic acid (30 mg/kg), 
the CAMP level was increased about 2-fold in 
plasma. 
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Fig.2. Cyclic nucleotide levels in liver and plasma of rats 
after griseolic acid administration. The columns show 
mean values f SE (n = 5) as nmol/ml plasma and 
nmol/g wet liver. Relative values for control are shown 
in parentheses. *p<O.O5, **p<O.Ol, ***p<O.COl by 
Students t-test for comparison with control value. 
3.3. Effect on glycogenolysis in mice 
When griseolic acid was administered in- 
travenously to mice (1 mg/kg), the blood glucose 
level was increased by about 2-fold and the liver 
glycogen level was decreased to 30% of the original 
level (fig.3). Similar changes in blood glucose and 
liver glycogen were observed by administration of 
glucagon (0.03 mg/kg), although the duration was 
shorter. Glucagon is known to exert its effect 
through the CAMP system by stimulation of adenyl 
cyclase [18]. Therefore, these results may be ex- 
plained by increase in CAMP level in the liver. 
3.4. Effect on lipolysis in fat cells 
The effects of griseolic acid on lipolysis and for- 
mation of CAMP were investigated with fat cells 
isolated from epididymal adipose tissue. Griseolic 
acid showed a stimulatory effect on lipolysis 
similar to theophylline (fig.4A). Under our condi- 
tions, griseolic acid caused accumulation of CAMP 
in the incubation medium containing fat cells 
(fig.4B). On the other hand, theophylline caused 
only a slight accumulation of CAMP. The lipolytic 
effect of theophylline may be due to properties 
other than its ability to inhibit PDE, in part, to its 
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Fig.3. Blood glucose and liver glycogen levels after 
griseolic acid administration to mice. Values are ex- 
pressed as average of 5 mice k SE. *p<O.OS, 
**p<o.o1, ***p<O.OOl by Students t-test for com- 
parison with control values. 
binding activity to adenosine receptor in fat cells 
v91. 
3.5. Cyclic AMP formation in cortex slices 
The effect of griseolic acid on the adenosine 
receptor was investigated on adenosine-elicited ac- 
cumulation of CAMP in guinea pig brain cortex 
slices. In this system, theophylline blocked the 
adenosine-elicited accumulation of CAMP [ 11,12, 
201. Griseolic acid, in contrast, had a stimulatory 
effect on the effect of adenosine, AMP, ADP and 
ATP (fig.5). The effect on CAMP accumulation of 
181 
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Fig.4. Effect of griseolic acid on lipolysis and CAMP 
levels in rat fat cells. Experiments were performed in 
duplicate. 
Fig.5. Effect of griseolic acid on adenosine-elicited 
accumulation of CAMP in cerebral cortex slices of 
guinea pigs. The columns show the mean values of 
duplicate experiments, and relative values for control are 
shown in parentheses. 
2 mM griseolic acid alone was less than that of 10 
PM adenosine. Griseolic acid seemed to have no 
binding activity to the adenosine receptor. 
3.6. Properties other than PDE inhibition 
Although griseolic acid has a similar structure to 
CAMP, it showed neither agonist nor antagonist 
activity on CAMP-dependent protein kinase par- 
tially purified from rat liver at 10e4 M, and showed 
no effect on adenyl cyclase activity of rat brain and 
on the adenosine deaminase from calf intestine. 
Griseolic acid showed no inhibitory effect on 
platelet aggregation or relaxation of guinea pig il- 
eum even at pg/ml, whereas papaverine, another 
well-known PDE inhibitor, relaxes the smooth 
muscle. 
Griseolic acid may become a unique and useful 
tool in biology to study the role of cyclic 
nucleotides. Potential new uses of griseolic acid or 
its analogues as a therapeutic agent will also con- 
tinue to be investigated. 
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